

# Ge Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7454461/publications.pdf>

Version: 2024-02-01

20  
papers

675  
citations

840776

11  
h-index

794594

19  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1294  
citing authors

#	ARTICLE	IF	CITATIONS
1	Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 559-568.	8.1	121
2	Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 20924.	3.3	6
3	Identification of low-density lipoprotein receptor class A domain containing 4 (LDLRAD4) as a prognostic indicator in primary gastrointestinal stromal tumors. <i>Current Problems in Cancer</i> , 2020, 44, 100593.	2.0	4
4	Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma. <i>Oncology Letters</i> , 2020, 21, 1-1.	1.8	10
5	High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma. <i>Oncology Letters</i> , 2018, 15, 931-939.	1.8	11
6	Genistein promotes ionizing radiation-induced cell death by reducing cytoplasmic Bcl-xL levels in non-small cell lung cancer. <i>Scientific Reports</i> , 2018, 8, 328.	3.3	28
7	The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma. <i>Cancer Medicine</i> , 2018, 7, 3889-3898.	2.8	8
8	Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. <i>BMC Cancer</i> , 2017, 17, 245.	2.6	25
9	EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. <i>Cancer Biology and Therapy</i> , 2016, 17, 320-327.	3.4	30
10	MicroRNA-21 regulates the expression of BTG2 in HepG2 liver cancer cells. <i>Molecular Medicine Reports</i> , 2015, 12, 4917-4924.	2.4	35
11	Clinical efficacy of percutaneous vertebroplasty combined with intensity-modulated radiotherapy for spinal metastases in patients with NSCLC. <i>OncoTargets and Therapy</i> , 2015, 8, 2139.	2.0	3
12	One-Carbon Metabolic Factors and Risk of Renal Cell Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0141762.	2.5	10
13	Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. <i>World Journal of Hepatology</i> , 2015, 7, 1964.	2.0	107
14	MicroRNAs involved with hepatocellular carcinoma (Review). <i>Oncology Reports</i> , 2015, 34, 2811-2820.	2.6	65
15	BTG2: A rising star of tumor suppressors (Review). <i>International Journal of Oncology</i> , 2015, 46, 459-464.	3.3	105
16	APE1 promotes antioxidant capacity by regulating Nrf-2 function through a redox-dependent mechanism. <i>Free Radical Biology and Medicine</i> , 2015, 78, 11-22.	2.9	15
17	High-incidence of PTEN mutations in Chinese patients with primary small cell carcinoma of the esophagus. <i>BMC Cancer</i> , 2014, 14, 19.	2.6	12
18	A method for generating large datasets of organ geometries for radiotherapy treatment planning studies. <i>Radiology and Oncology</i> , 2014, 48, 408-415.	1.7	3

#	ARTICLE	IF	CITATIONS
19	Identification and Characterization of Mitochondrial Targeting Sequence of Human Apurinic/Apyrimidinic Endonuclease 1. Journal of Biological Chemistry, 2010, 285, 14871-14881.	3.4	77
20	Rapid induction of mRNA for Tec genes by hepatopoietin and partial hepatectomy. Chinese Journal of Digestive Diseases, 2002, 3, 154-158.	1.0	0